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Abstract The purpose of this investigation was to explore the
presumed relationship between the days of hospitalisation and
microorganisms identified by endotracheal aspirate cultures in
relation to adequate empirical treatment strategies of pneumo-
nia in the intensive care unit (ICU). All potentially pathogenic
microorganisms identified by (surveillance) cultures of endo-
tracheal aspirates obtained in the ICUs of two Dutch teaching
hospitals in 2007 and 2012 were retrospectively collected and
analysed. Antibiotic susceptibilities to 11 antibiotics were cal-
culated for several time points (days or weeks) after hospital
admission and expressed per patient-day. In total, 4184 poten-
tially pathogenic microorganisms identified in 782 patients
were analysed. Prevalence of the classic early-onset pneumo-
nia-causing microorganisms decreased from 55 % on the first
four days to 34 % on days 4–6 after hospital admission
(p<0.0001). Susceptibility to amoxicillin/clavulanic acid
was below 70 % on all days. Except for days 0 and 12, sus-
ceptibility to ceftriaxone was below 80%. The overall suscep-
tibility to piperacillin/tazobactam was 1518/1973 (77 %) in
2007 vs. 727/1008 (67 %) in 2012 (p<0.0001). After day 8
of hospital admission, susceptibility to piperacillin/
tazobactam therapy was below 80 % in 2012. After
one week of hospital admission, susceptibilities to antibiotics
were lower in the hospital that included that antibiotic in the
local empirical treatment protocols as compared to the hospi-
tals in which that antibiotic was not or infrequently included:
90/434 (21 %) vs. 117/398 (29 %); p=0.004 for amoxicillin/
clavulanic acid and 203/433 (47 %) vs. 253/398 (64 %);
p<0.001 for ceftriaxone. No cut-off in the number of days
after hospital admission could be identified to distinguish
early-onset from late-onset pneumonia. Consequently, the
choice of empirical antibiotics should probably not be based
on the time of onset.
Introduction
Pneumonia in the intensive care unit (ICU) is associated with
significant mortality, morbidity and costs [1, 2]. Early and
appropriate antibiotic treatment reduces pneumonia mortality
[3], but unnecessary and inappropriate antibiotic use leads to
redundant side effects, costs and promotes antibiotic resis-
tance [4, 5]. Selecting the most optimal empirical antibiotic
treatment of pneumonia in ICUs should depend on many fac-
tors, such as suspected causative microorganism, local resis-
tance profiles, specific pharmacological and pharmacodynam-
ic characteristics, local protocols and antibiotic costs. A spe-
cific number of hospital admission days prior to pneumonia
development is frequently used as a cut-off after which anti-
biotic therapy is switched in order to target more multidrug-
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resistant (MDR) and hospital-acquired microorganisms [6].
For ventilator-associated pneumonia (VAP), the distinction
between early-onset and late-onset VAP is, therefore, fre-
quently made. However, the cut-off in the number of days to
distinguish late-onset from early-onset VAP is used inconsis-
tently. In 1987, late-onset VAP was defined as a pneumonia
that developed after 5 days of ICU admission [7], whereas
5 days [8] or 7 days [9, 10] after the start of mechanical
ventilation are likewise used. Studies using 5 days after intu-
bation or 4–7 days after ICU admission as the cut-off value
demonstrated nomicrobiological differences in the prevalence
of potential MDR microorganisms between both groups [8,
11]. Indeed, a cut-off of 5 days after hospital admission may
bemore rational, since patients who are hospitalised for five or
more days before intubation will harbour microorganisms
more commonly associatedwith late-onset pneumonia [6, 12].
Potentially pathogenic microorganisms previously identi-
fied by (surveillance) cultures of endotracheal aspirates
(ETAs) are, regardless of quantification, known to be frequent
causes of subsequently developed VAP [13]. Indeed, the di-
agnosis of VAP is frequently confirmed by these ETA cultures
[6, 14, 15]. Additionally, antibiotic guidance by surveillance
cultures in a hypothetic model of 223 hospital-acquired pneu-
monia patients resulted in the use of a smaller number of
broad-spectrum antibiotics without reducing appropriateness
[16]. Because clinicians aim to target these previously identi-
fied microorganisms in the case where pneumonia develops
[17], one could hypothesise that the results of antibiotic sus-
ceptibility of these ETA cultures could be useful to analyse the
general appropriateness of empirical antibiotics.
In the perspective of this assumption, the current study
aims to explore whether a cut-off value in days after hospital
admission can be identified which best distinguishes early-
from late-onset pneumonia in the ICU. This study also pro-
vides insight into the most appropriate empirical treatment
depending on the time after admission. Furthermore, differ-
ences between two different years and hospitals concerning
MDR development are appraised.
Methods
Setting
The study was conducted in two medical centres in the
Netherlands (known for relatively low MDR rates [18]); the
Maastricht University Medical Centre, a 715-bed tertiary uni-
versity medical centre with approximately 30,000 admissions
annually and 27 ICU beds (further referred to as hospital A),
and the Zuyderland Medical Centre Heerlen, a general 1230-
bed teaching hospital (19 km from hospital A) with approxi-
mately 30,000 admissions annually and 21 ICU beds (hospital
B). Surveillance cultures of ETAwere obtained twice weekly
from all mechanically ventilated patients in both hospitals.
Furthermore, ETA cultures were performed under the suspi-
cion of an infection. When pneumonia was present and no
results of previously obtained cultures were available for an-
tibiotic guidance, empirical treatment algorithms were differ-
ent in the two hospitals. In hospital A, ICU patients that de-
velop pneumonia within the first four days of hospital admit-
tance receive amoxicillin/clavulanic acid frequently with cip-
rofloxacin and piperacillin/tazobactam when admitted to the
ICU after four preceding days of admission to a hospital ward.
In hospital B, ICU patients that developed pneumonia within
the first four days of hospital admittance receive either
amoxicillin/clavulanic acid or ceftriaxone including ciproflox-
acin. When the pneumonia developed after four days of hos-
pital admittance, piperacillin/tazobactam is usually adminis-
tered. In both hospitals, the ciprofloxacin is stopped when the
patient recovers and the urine Legionella antigen test is nega-
tive. The attendance of a consulting medical microbiologist in
daily multidisciplinary ICU meetings contributes to good an-
tibiotic stewardship.
In hospital A, selective oropharyngeal decontamination
(SOD) use was implemented in December 2010 and selective
digestive tract decontamination (SDD), which includes SOD,
was implemented after January 2012 in patients expected to
stay in the ICU for more than 48 h. In 2012, hospital B used
oropharyngeal decontamination with chlorhexidine. In 2007,
the hospitals used neither SOD nor SDD. The ethics commit-
tees of both the institutions approved the study. Informed con-
sent was not necessary, since it concerned a retrospective
study evaluating standard patient care and patients’ privacy
was respected.
Design and definitions
All potentially pathogenic microorganisms, including their
antibiotic susceptibility to 11 frequently used antibiotics, iden-
tified by (surveillance) cultures of ETA obtained in 2007 and
2012 were retrospectively collected. In hospital A, the data
query was used from a Phoenix automated microbiology sys-
tem for susceptibility testing (DB Diagnostics, Sparks, MD,
USA) and from the laboratory information system (Labosys,
Philips, Eindhoven, The Netherlands). In hospital B, the data
query was performed using VITEK 2 (automated system for
microorganisms identification and antibiotic susceptibility
testing; bioMérieux, Inc., Durham, NC, USA). Endotracheal
aspirates were cultured semiquantitatively and growth was
expressed as sporadic, little, moderate or heavy. As no thresh-
old for positivity is known for semiquantitative cultures of
ETA, all positive results were included. Clinical data were
received from patient data management systems. In case mul-
tiple identical microorganisms with identical antibiotic sus-
ceptibility were identified on the same day in the same patient,
only one microorganism was included in the susceptibility
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analysis. The included microorganisms were subsequently ar-
ranged according to the number of days after hospital admis-
sion the ETA sample was collected. Subsequently, antibiotic
susceptibility on a specific day after hospital admission was
calculated and expressed per patient-day. The latter signifies
that, in case multiple microorganisms were identified in the
same patient on the same day after hospital admission, sus-
ceptibility to a specific antibiotic was defined only when all
microorganisms identified on a specific day after hospital ad-
mission were susceptible to that antibiotic. All ETA cultures
were analysed regardless of being surveillance cultures or cul-
tures taken for suspected pneumonia, and regardless of the
presence or absence of infection. Based on the elucidation in
the introduction, antibiotic appropriateness may, thus, be
equal to the calculated susceptibility of all microorganisms
identified that day in one patient to a specific antibiotic.
Consequently, one can extrapolate the appropriateness of dif-
ferent empirical antibiotics on any day after hospital admis-
sion a pneumonia (hypothetically) presents. The classical
early-onset VAP microorganisms are Streptococcus
pneumoniae, Haemophilus influenzae, Moraxella catarrhalis
and (methicillin-sensitive) Staphylococcus aureus. By com-
paring antibiotic susceptibility between different days after
hospital admission, the most rational cut-off in days for
early- and late-onset VAP and, consequently, antibiotic
change can be identified. Ameta-analysis of 87 studies report-
ed a pooled rate of appropriate empirical antibiotic treatment
of 71.4 % [95 % confidence interval (CI) 68.2–74.6] [19].
Additional literature concerning the optimal and/or acceptable
cut-off in the number of days to strive for is currently lacking.
Therefore, hypothetically, antibiotic appropriateness was arbi-
trarily defined as follows: at least 80 % of the microorganisms
identified on a particular day (per patient) after hospital ad-
mission should be susceptible to the appraised antibiotic. In
order to determine whether differences in susceptibility arise
due to differences in empirical antibiotic use, antibiotic sus-
ceptibilities after one week of hospitalisation were compared
between the hospitals.
Antibiotic susceptibility
The susceptibility patterns of the following antibiotics were
collected: amoxicillin, amoxicillin/clavulanic acid, ceftazi-
dime, ceftriaxone, ciprofloxacin, gentamicin, meropenem, pi-
peracillin, piperacillin/tazobactam, vancomycin and trimetho-
prim/sulphamethoxazole. The antibiotic susceptibility of all
samples obtained in 2007 were adjusted to European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) v 2.0 guidelines (introduced in 2010 [20]) to en-
sure their comparability to the 2012 cohort. When susceptibil-
ity was not tested and the EUCAST did not provide presumed
susceptibility, suppositions were made in the following cases
(partly based on the low–mediocre MDR situation in the
Netherlands [21]):
& Moraxella catarrhalis was considered susceptible to
ciprofloxacin.
& Streptococcus pneumoniae was considered susceptible to
meropenem and resistant to ceftazidime.
& Enterobacteriaceae and M. catarrhalis susceptible to
amoxicillin were presumed to be susceptible to piperacil-
lin and, if susceptible to amoxicillin/clavulanic acid, sus-
ceptibility to piperacillin/tazobactam was presumed.
& When Pseudomonas aeruginosa was susceptible to
imipenem, susceptibility to meropenem was presumed.
& Susceptibility of H. influenzae, S. pneumoniae and
M. catarrhalis to gentamicin was neither tested nor
known. Therefore, these microorganisms were excluded
in the susceptibility testing of gentamicin and excluded
from the calculations.
& In case of methicillin-resistant S. aureus (MRSA), resis-
tance to meropenem and piperacillin/tazobactam was not
tested by standard practice and was, therefore, deduced.
In hospital B, susceptibility testing of Enterobacteriaceae to
piperacillin was not routinely performed and, consequently,
the appropriateness of piperacillin therapy was not speculated
upon.
Exclusion criteria
Commensal flora (Candida spp., coagulase-negative staphy-
lococci, Corynebacterium spp., enterococci, Neisseria spp.,
oropharyngeal flora, Elizabethkingia meningoseptica,
Streptococcus viridians group and yeasts) were considered
non-pathogenic and, subsequently, these organisms were not
included, consistent with previous studies and guidelines
[22–24]. Stenotrophomonas maltophilia was excluded from
the antibiotic susceptibility analysis due to high intrinsic resis-
tance rates, whereas pathogenicity is considered to be limited
[25, 26]. Sphingomonas paucimobilis, Alcaligenes
xylosoxidans, Pseudomonas putida and miscellaneous non-
fermenters were rarely identified and were excluded from
the susceptibility analysis.
Statistics
An associate professor in statistics advised regarding the data
analysis. Numbers are presented as the mean including stan-
dard deviation when appropriate. Percentages are given as
integers. Due to the fact that more microorganisms than pa-
tients were included, differences in microorganism prevalence
between the two hospitals and years were expressed in
corrected odds ratio (COR), using generalised estimating
equations correcting for microorganisms that are repeatedly
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cultured in the same patient. Differences in incidences of a
categorical variable between two groups were calculated
using the Pearson Chi-square test. In order to define the best
cut-off point in days after hospital admission to differentiate
early-onset VAP from late-onset VAP, the most clear and per-
manent drop in antibiotic susceptibility between two consec-
utive days after hospital admission was visualised and subse-
quently used. IBM SPSS Statistics version 23 for Windows
(Chicago, IL, USA) was used for the analyses.
Results
General findings
From the 6524 ETA samples obtained during the studied pe-
riod, 4184 potentially pathogenic microorganisms from 782
patients were identified. Table 1 provides information regard-
ing general patient characteristics, indications for ICU admis-
sion and the bacteria identified. In both hospitals, more poten-
tially pathogenic microorganisms were identified in 2007
compared to 2012 (total 2643 vs. 1541).
The most common indications for ICU admission were
respiratory failure (22 %), post cardiovascular surgery and
abdominal surgery (both 15 %). In hospital A, cardiovascular
surgery and neurological surgery were more frequently the
reasons for ICU admission, as compared to hospital B (23 %
vs. 6 % [p<0.001] and 9 % vs. 1 % [p<0.001], respectively).
In hospital B, abdominal surgery was more frequently the
reason for ICU admission compared to hospital A (21 % vs.
10 % [p<0.001]).
Identifiedmicroorganisms per study year and per hospital
Overall, P. aeruginosa, S. aureus, Escherichia coli and
Klebsiella spp. were the most frequently identified microor-
ganisms; 1147 (27 % of the total identified potentially patho-
genic microorganisms), 540 (13 %), 511 (12 %) and 424
(10 %) times, respectively. All COR including 95 % CIs and
p-values regarding the prevalence of microorganisms identi-
fied in 2012 vs. 2007 and in hospital B vs. hospital A are
provided in Appendix 1.
Pseudomonas aeruginosa was less frequently identified in
2012 as compared to 2007; 285 vs. 862 times (COR 0.470
[95 % CI 0.262–0.843] p=0.011). Stenotrophomonas
maltophilia, Proteus spp., Serratia spp. and H. (para)-
influenzae were relatively more frequently isolated in 2012
as compared to 2007: 135 vs. 84 times (COR 2.988 [95 %
CI 1.458–6.126] p=0.003), 99 vs. 91 times (COR 1.881 [95%
CI 1.020–3.467] p=0.043), 184 vs. 140 times (COR 2.563
[95 % CI 1.271–5.169] p=0.009) and 67 vs. 70 times (COR
1.642 [1.027–2.626] p=0.038), respectively.
Staphylococcus aureus was more frequently isolated in
hospital B as compared to hospital A; 339 vs. 201 times
(COR 2.589 [95 % CI 1.799–3.725] p<0.001). Gram-
negative microorganisms were significantly less frequently
isolated in hospital B as compared to hospital A; 1394/1773
(79 %) vs. 2179/2411 (90 %) (COR 0.394 [95 % CI 0.279–
0.555] p<0.001). Both M. catarrhalis and Morganella
morganii were more frequently isolated in hospital B as com-
pared to hospital A: 32 times vs. 11 times (COR 4.062 [95 %
CI 1.777–9.285] p=0.001) and 35 vs. 19 times (COR 2.763
[95 %CI 1.120–5.816] p=0.027). Acinetobacter spp. was less
frequently isolated in hospital B as compared to hospital A; 33
vs. 154 times (COR 0.201 [95 % CI 0.076–0.526] p=0.001).
Prevalence of microorganisms according to the day
after hospital admission
A total of 3948 samples from 752 patients were included in the
analyses concerning prevalence according to the day after hos-
pital admission and antibiotic susceptibility. Figure 1 presents the
prevalence of different microorganisms identified in ETA sam-
ples in the first week of hospital admission arranged according to
the day after hospital admission in 2007 and 2012. A complete
overview of the prevalence of specific microorganisms in the
different years in specific days or weeks after hospital admission
is provided in the Supplementary material. In Fig. 1, the black
line indicates the percentage of classical early-onset pneumonia
pathogens. In the first four days of admission, these microorgan-
isms represent 55 % of all identified potentially pathogenic mi-
croorganisms (124/228 [54 %] in 2007 and 116/209 [56 %] in
2012), whereas in the last three days of the first week, these
microorganisms represent 34 % (69/199 [35 %] in 2007 and
38/116 [33 %] in 2012; p<0.0001 for comparing these different
periods in both years). In 2007, P. aeruginosa represented 483/
978 (49%) of all microorganisms identified in ETA after week 5,
whereas in 2012, P. aeruginosa rates increased every week to a
steady 28 % (127/458) after week 3 (see Supplementary
material). Serratia spp., which were more frequently identified
in 2012 compared to 2007, represented 10–20 % of all poten-
tially pathogenic microorganisms identified in the period after
hospitalisation, although less in the first week (26/325 [8%]) and
significantly more after week 10 (30/133 [25 %], p<0.001) in
2012 (see also Supplementary material).
Antibiotic susceptibly testing
Antibiotic susceptibility testing results per patient-day in the
first two weeks after hospital admission and the results ar-
ranged including the weeks thereafter are presented in
Figs. 2 and 3. The presentation of the results is bisected in
the two observed years. Looking at the first four days of hos-
pital admission in 2012, susceptibility to amoxicillin/
clavulanic acid was 104/164 (63 %), whereas on days 4–6,
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susceptibility revealed 37/91 (41 %) on days 4–6 (p=0.0007).
Indeed, in the transition from day 3 to day 4 of hospital
admission, susceptibility dropped from 62 % (29/47) on day
3 to 42 % (16/38) on day 4 (p=0.072).
Table 1 Patient characteristics and endotracheal aspirates culture results
Hospital A Hospital B Total
Year 2007 2012 2007 2012 2007 and 2012
ICU admissions 1688 1807 1347 1271 6113
Samples obtained 1759 1550 1849 1366 6524
PPMO identified 1595 816 1048 725 4184
Patients 234 194 194 160 782
Mean age, years (SD) 63 (15) 61 (14) 68 (12) 65 (14) 64 (14)
Male (%) 147 (63) 137 (71) 126 (65) 105 (66) 515 (66)
Indication for ICU admission (% of patients)a
Non-surgical 81 (35 %) 105 (54 %) 120 (62 %) 105 (66 %) 411 (53 %)
Respiratory 43 (18 %) 34 (18 %) 43 (22 %) 51 (32 %) 171 (22 %)
Neurological 12 (5 %) 20 (10 %) 22 (11 %) 15 (9 %) 69 (9 %)
Post cardiac arrest 4 (2 %) 16 (8 %) 15 (8 %) 19 (12 %) 54 (7 %)
Cardiovascular 6 (3 %) 8 (4 %) 19 (10 %) 12 (8 %) 45 (6 %)
Abdominal 6 (3 %) 6 (3 %) 10 (5 %) 5 (3 %) 27 (3 %)
Surgical 153 (65 %) 89 (46 %) 74 (38 %) 55 (34 %) 371 (47 %)
Cardiovascular 58 (25 %) 42 (22 %) 15 (8 %) 5 (3 %) 120 (15 %)
Abdominal 31 (13 %) 12 (6 %) 43 (22 %) 30 (19 %) 116 (15 %)
Trauma 20 (9 %) 12 (6 %) 6 (5 %) 6 (4 %) 44 (6 %)
Neurological 24 (10 %) 15 (8 %) 2 (1 %) 2 (1 %) 43 (5 %)
Bacteria identified (% of total PPMO identified)
Gram-positive 147 (9 %) 85 (10 %) 222 (21 %) 157 (22 %) 611 (15 %)
Staphylococcus aureus 126 (8 %) 75 (9 %) 201 (19 %) 138 (19 %) 540 (13 %)
Of which MRSA 4 9 (1 %) 9 (1 %) 22 (1 %)
Streptococcus pneumoniae 21 (1 %) 10 (1 %) 21 (2 %) 19 (3 %) 71 (2 %)
Gram-negative 1448 (91 %) 731 (90 %) 826 (79 %) 568 (78 %) 3573 (85 %)
Non-fermenters 689 (43 %) 308 (38 %) 428 (41 %) 182 (25 %) 1607 (38 %)
Acinetobacter spp. 122 (8 %) 32 (4 %) 17 (2 %) 6 (1 %) 177 (4 %)
Moraxella catarrhalis 6 5 (1 %) 22 (2 %) 10 (1 %) 43 (1 %)
Pseudomonas aeruginosa 520 (33 %) 159 (19 %) 342 (33 %) 126 (17 %) 1147 (27 %)
Stenotrophomonas maltophilia 37 (2 %) 99 (12 %) 47 (4 %) 36 (5 %) 219 (5 %)
Other non-fermenters (e.g. S. paucimobilis, A. xylosoxidans) 4 13 (2 %) 4 (1 %) 21 (1 %)
Enterobacteriaceae 725 (45 %) 386 (47 %) 360 (34 %) 355 (49 %) 1826 (44 %)
Citrobacter spp. 18 (1 %) 9 (1 %) 11 (1 %) 13 (2 %) 51 (1 %)
Enterobacter spp. 112 (7 %) 54 (7 %) 46 (4 %) 32 (4 %) 244 (6 %)
Escherichia coli 217 (14 %) 104 (13 %) 110 (10 %) 80 (11 %) 511 (12 %)
Klebsiella spp. 191 (12 %) 56 (7 %) 91 (9 %) 86 (12 %) 424 (10 %)
Morganella morganii 17 (1 %) 1 21 (2 %) 14 (2 %) 53 (1 %)
Proteus spp. 45 (3 %) 48 (6 %) 46 (4 %) 51 (7 %) 190 (5 %)
Serratia spp. 120 (8 %) 109 (13 %) 20 (2 %) 75 (10 %) 324 (8 %)
Other Enterobacteriaceae (e.g. Hafnia alvei, Kluyvera spp., Raoultella planticola) 5 5 (1 %) 15 4 (1 %) 29 (1 %)
Miscellaneous
Haemophilus (para-)influenzae 34 (2 %) 36 (4 %) 36 (3 %) 31 (4 %) 137 (3 %)
Other species 1 2 3
Included for prevalence and susceptibility analysis
Patients 230 (98 %) 181 (93 %) 187 (96 %) 154 (96 %) 752 (96 %)
Microorganisms 1554 (97 %) 704 (86 %) 1001 (96 %) 689 (95 %) 3948 (94 %)
If no numbers and/or percentages are provided, the incidences and/or percentages are equal to zero
ICU Intensive care unit; MRSA methicillin-resistant Staphylococcus aureus; PPMO potentially pathogenic microorganisms; SD standard deviation
a Infrequent indications for ICU admission were not incorporated
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Apart from a peak on day 12 (12/15 [80 %]), susceptibility to
ceftriaxone remained below 80 % after the day of hospital ad-
mission. In 2012, more microorganisms yielded by ETA were
susceptible to ceftriaxone after four days of hospitalisation (412/
884 [47 %] in 2012 vs. 617/1736 [36 %] in 2007 [p<0.0001])
and to trimethoprim/sulphamethoxazole after three days (590/
823 [64 %] in 2012 vs. 809/1787 [45 %] in 2007 [p<0.0001]).
Overall, susceptibility to piperacillin/tazobactam and ceftaz-
idime declined during this 5-year period; 1518/1973 (77 %) in
2007 vs. 727/1008 (67 %) in 2012 (p<0.0001) for piperacillin/
tazobactam and 1176/1975 (60%) in 2007 vs. 492/1087 (45%)
in 2012 [p<0.0001] for ceftazidime (not included in the graph).
In 2012, susceptibility to piperacillin/tazobactam did not ex-
ceed 80 % after day 8 and remained below 70 % after day 12
of hospital admission. Meropenem susceptibility after 4 weeks
of hospital admission was 85% (766/896) in 2007 compared to
81 % (341/420) in 2012 (p=0.047).
Differences in antibiotic susceptibility between the two
hospitals
For the four most frequently prescribed antibiotics, an analysis
comparing susceptibility after one week of hospitalisation be-
tween the hospitals in 2012 was done. Ciprofloxacin and cef-
triaxone susceptibility was higher in hospital A; 326/434
(75 %) vs. 263/398 (66 %); p=0.004 for ciprofloxacin and
230/433 (53 %) vs. 145/398 (36 %); p<0.001 for ceftriaxone.
Susceptibility to amoxicillin/clavulanic acid was higher in
hospital B; 117/398 (29 %) vs. 90/434 (21 %); p=0.004.
Susceptibility to piperacillin/tazobactam was equal in both
hospitals; 271/434 (62 %) in hospital A vs. 254/396 (64 %)
in hospital B; p=0.610.
Discussion
This study provides insight into the microorganisms yielded
by (surveillance) cultures of ETA arranged according to the
day after hospital admission and their susceptibility to fre-
quently used antibiotics. Accordingly, possibly unconvention-
al insights into the rationale of empirical antibiotic therapy for
pneumonia in ICUs, including its appropriateness over time,
are provided. Whereas the susceptibility to some frequently
used antibiotics significantly and relevantly declined in the
last 5 years, other antibiotics demonstrated a more steady sus-
ceptibility pattern, even after weeks of hospital admission.
Overall, this study endorses the increasing problem of MDR
development. In the following paragraphs, several noticeable
results are presented and discussed in the light of the currently
available literature.
2012 vs. 2007
In 2012, significantly less potentially pathogenic microorgan-
isms (especially P. aeruginosa) were identified compared to
2007, which could be explained by SOD/SDD use [27] in
hospital A and chlorhexidine use and the more frequent use
of meropenem in hospital B (166 in 2007 vs. 367 in 2012
[expressed in daily defined dose]). Furthermore, fewer sam-
ples were obtained in 2012 compared to 2007. As
S. maltophilia was increasingly identified, the significance
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Fig. 1 Prevalence of different microorganisms yielded by endotracheal
aspirate samples in the first week of hospitalisation in 2007 and in 2012.
The black line indicates the percentages of classical early-onset
pneumonia pathogens (Streptococcus pneumoniae, Haemophilus
influenzae, Moraxella catarrhalis and Staphylococcus aureus). MRSA
Methicillin-resistant Staphylococcus aureus
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of the presence of this notorious MDR microorganism [26] in
the ICU remains an interesting subject for further studies.
Early-onset vs. late-onset VAP
From an aetiological point of view, the classical early-onset
pathogens were significantly less often present after four days
of hospitalisation. However, the decrease in incidence of these
early-onset microorganisms was less clear than perhaps ex-
pected. One may, therefore, question whether the term ‘ear-
ly-onset’ is still applicable, since 45 % of the pathogens iden-
tified in the first four days of hospitalisation were not identi-
fied as early-onset pathogens. The risk that a late-onset path-
ogen is involved in this traditionally early-onset period is,
thus, high, which may impact on the choice of empirical anti-
biotic therapy. On the other hand, the 45 % could be a over-
estimation, as S. pneumonia and Legionella pneumophila are
possibly underrepresented: Streptococcus pneumoniae is eas-
ily killed by pre-culture administered penicillin and both bac-
teria might be identified by tests other than ETA cultures, such
as blood culture and urine antigen testing [28].
Whereas susceptibility to amoxicillin/clavulanic acid de-
clined similarly from 62 % on day 3 to 42 % on day 4 in
2012, this is probably irrelevant, as even 62 % susceptibility
is too low. Whereas other antibiotics did not demonstrate such
decline, no real cut-off could be pinpointed from the results
from a treatment point of view. Indeed, recent studies support
these findings and classifying VAP patients based on the time
of onset does not result in the generation of two groups with
different MDR rates [29] and results in under- and overtreat-
ment [30]. Overall, the difference between early-onset and
late-onset VAP is, thus, increasingly blurred and is probably
irrelevant from an antibiotic treatment perspective. One won-
ders whether this nomenclature can be abandoned in contem-
porary practice, since its use appears to become obsolete.
Empirical antibiotic appropriateness
When empiric VAP therapy is initiated irrespectively of ETA
(surveillance) cultures results or knowledge of previously ad-
ministered antibiotics, one may assume that the provided an-
tibiotic susceptibilities could be interpreted as appropriate-
ness of this antibiotic for pneumonia developing on a specific
day after hospital admission. Under this assumption,
amoxicillin/clavulanic acid would have been inappropriate at
all times and ceftriaxone would have been only appropriate as
empirical therapy on the first day of hospital admission. In
2012, piperacillin/tazobactam would have been inappropriate
after day 8 of hospital admission, whereas in 2007,
piperacillin/tazobactam overall appropriateness would reveal
Fig. 2 Susceptibility of all potentially pathogenic microorganisms yielded by endotracheal aspirates to different antibiotics in the first two weeks after
hospital admission in 2007 and 2012
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77 %. In reality, appropriateness of the tested antibiotics is
probably higher if the results of previously obtained ETA
(surveillance) cultures, previously administered antibiotics
and clinical features are taken into account before pneumonia
treatment is started, hence accentuating their importance for
pneumonia management in the ICU. Indeed, when the results
of previously obtained (surveillance) cultures of ETAs are
known, antibiotics will be adjusted accordingly [13, 16, 31].
Furthermore, less broad-spectrum antibiotics can likely be
used when only previously yielded microorganisms are
targeted [16], thereby decreasing the chances of MDR devel-
opment [4] and providing good antibiotic stewardship [5].
Taking into account the costs (7 € per daily defined dose,
excluding the blood drug level determination costs) and stable
appropriateness level, gentamicin would appear to be the
choice for empirical pneumonia treatment on ICUs.
However, aminoglycosides are suboptimal for lung tissue pen-
etration [32] and have adverse effects on auditory [33] and
renal function [34, 35]. Additionally, the susceptibility of
H. influenzae, S. pneumoniae and M. catarrhalis to gentami-
cin was neither tested nor known, but these microorganisms
are uncommon after 1–2 weeks of hospitalisation (see
Supplementary material).
Likewise, ciprofloxacin performed reasonably several
weeks after hospital admission, and despite concerns about
MDR development [36] and Clostridium difficile-associated
diarrhoea [37], it may have a role as an initial empirical agent
until microbiological test results are available.
Differences between hospitals
Several differences in microorganism prevalence and antibi-
otic susceptibility between two neighbouring hospitals were
revealed. Whereas S. aureus,M. catarrhalis andM. morganii
were identified significantly more often in hospital B,
Acinetobacter spp. were significantly less frequently identi-
fied in hospital B as compared to hospital A. Overall, antibi-
otic susceptibility was lower in hospital A, possibly due to
more overall antibiotic use in the ICU of university hospitals
compared to ICUs in non-university hospitals [38]. After
one week of hospital admission, susceptibility to antibiotics
was revealed to be significantly higher in the hospital that did
infrequently incorporate that antibiotic in their empirical anti-
biotic protocol (hospital A ceftriaxone; hospital B amoxicillin/
clavulanic acid). Susceptibi l i ty to tr imethoprim/
sulphamethoxazole, which are infrequently used in both hos-
pitals, increases over the 5-year period in both hospitals.
These two findings suggest that infrequently used antibiotics
may be more appropriate in the future, as resistance to these
antibiotics is fading away, as described previously [39, 40]. In
order to prevent resistance, it could, thus, be justified to peri-
odically adapt empirical therapy, a strategy which is called
Fig. 3 Antibiotic susceptibility of all potentially pathogenic microorganisms yielded by endotracheal aspirates arranged per patient-day in the first
two weeks and per week thereafter
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antibiotic cycling or rotation. Available studies concerning
this strategy are contradictory [41–43], leaving it an interest-
ing topic for further studies. The differences between the two
hospitals emphasise the need for local microbiological surveil-
lance and mapping for better pneumonia treatment [6, 44, 45].
Limitations
Apart from the limitations inherent to the hypothetic model
and the probable underrepresentation of S. pneumoniae and
L. pneumophila, some other limitations should be addressed.
First, all positive ETA culture results were included regardless
of whether they were taken for surveillance or for suspected
VAP. Including exclusively (suspected) VAP cases, as done in
previous and partly similar research [10], would increase the
strength of the study method. Yet, the high numbers of micro-
organisms herein identified and studied would then never
have been achieved. Second, the number of readmissions,
admission from nursing homes, medical history (e.g. chronic
obstructive pulmonary disease, cystic fibrosis or immune
state) and pre-admission culture results were not available.
Lack of this information may at least partly explain the early
presence of ‘late-onset’microorganisms and could have influ-
enced the choice of empirical therapy in actual practice, since
they increase the risk of MDR microorganism involvement
[6]. Third, correction for antibiotic use was not applied.
When mechanically ventilated patients receive antibiotics,
colonisation with resistant bacteria may occur. Fourth and last,
susceptibility analyses were expressed per patient-day. As a
result, patients with a prolonged hospital stay may be respon-
sible for a superabundant number of microorganisms in the
weeks far beyond hospital admission. This may have
overestimated antibiotic resistance and the results of those
weeks should, thus, be viewed in this perspective. Yet, a su-
perior way to express the antibiotic susceptibility in a hospital
on a given day after admission is not available. However,
depending on the study design, the expression may be based
on isolate, patient, episode and/or resistance phenotype [46].
Conclusions
This study provides insights into microorganism prevalence in
endotracheal aspirate (ETA) cultures in the intensive care unit
(ICU) and its antibiotic susceptibility. With the method used,
no purposeful cut-off could be determined to distinguish
early- from late-onset ventilator-associated pneumonia
(VAP) from a treatment point of view. Therefore, classifying
VAP based on the time of onset has perhaps become obsolete.
Amoxicillin/clavulanic acid resistance appeared high during
all days of hospital admissions, whereas piperacillin/
tazobactam resistance was high after eight days of
hospitalisation. The decline during hospital admission in
susceptibility to frequently empirically used antibiotics was
more explicit in the hospital that incorporated that antibiotic
in empirical treatment protocols. Overall, adapting empirical
pneumonia therapy on previously known results of surveil-
lance cultures appeared rewarding in order to increase the
appropriateness of therapy.
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